Effects of individualized nutrition intervention on sarcopenia and quality of life in maintenance hemodialysis patients

CHENG Hongjuan; ZHOU Wei; ZHA Bai; WANG Jianping; CHEN Qiming; WU Xiaorong

doi:10.7619/jcmp.20231695

Journal of Clinical Medicine in Practice > 2023 > 27(15): 62-67. > DOI: 10.7619/jcmp.20231695

CHENG Hongjuan, ZHOU Wei, ZHA Bai, WANG Jianping, CHEN Qiming, WU Xiaorong. Effects of individualized nutrition intervention on sarcopenia and quality of life in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2023, 27(15): 62-67. DOI: 10.7619/jcmp.20231695

Citation:

PDF (718 KB)

Effects of individualized nutrition intervention on sarcopenia and quality of life in maintenance hemodialysis patients

Department of Nephrology, Nanjing Gaochun People's Hospital of Jiangsu Province, Nanjing, Jiangsu, 211300

More Information

Received Date: May 25, 2023
Revised Date: July 06, 2023
Available Online: September 03, 2023

Graphical Abstract

Abstract

Abstract

Objective
To explore effects of individualized nutrition intervention on sarcopenia and quality of life in maintenance hemodialysis(MHD)patients.
Methods
A total of 102 patients who received regular hemodialysis for more than 6 months were selected as research objects, and their general data were collected, biochemical indexes were detected, and skeletal muscle mass index, grip strength and daily walking speed were measured. According to the diagnostic criteria of Asian Sarcopenia Working Group (AWGS), the objects were divided into sarcopenia-free group(n=74) and sarcopenia group(n=28). Patients in both groups were given individualized nutritional intervention for 3 months, and the changes of sarcopenia and quality of life before and after treatment were compared. The clinical data and related indicators of sarcopenia (skeletal muscle mass index, grip strength, daily walking speed) and quality of life[36-item Shot-form Health Status Survey(SF-36)]score of the two groups were compared before and after treatment.
Results
Among 102 subjects, the incidence of sarcopenia was 27.45%(28/102), and there were statistical differences in age, sex, body mass index, serum albumin, hypersensitive C-reactive protein, blood urea nitrogen, blood creatinine between the two groups (P < 0.05). Before treatment, the physiological function, body pain, general health dimension score, total score in physical health field and total score of SF-36 Scale in the sarcopenia group were lower than those of the sarcopenia-free group (P < 0.05). After treatment, the skeletal muscle mass indexes and grip strength of two groups were higher than before treatment, and skeletal muscle mass indexes and the difference value of grip strength before and after treatment of the sarcopenia group were greater than those of sarcopenia-free group (P < 0.05). There was no significant difference in daily walking speed between two groups before and after treatment (P>0.05). After treatment, the physiological function, general health status, energy dimension score, total score of physiological health field and total score of SF-36 Scale of MHD patients were higher than before treatment (P < 0.05).
Conclusion
The prevalence of sarcopenia in MHD patients is high, which is related to age, gender, nutritional status and microinflammation, and seriously affects the quality of life of patients. Individualized nutritional intervention therapy can effectively relieve the sarcopenia and improve the quality of life of patients.
- nutrition intervention,
- sarcopenia,
- quality of life,
- maintenance hemodialysis

FullText(HTML)

References (23)

References

[1]	周起帆, 尹丽霞, 张海林, 等. 中青年维持性血液透析患者肌少症预测模型的构建与验证[J]. 实用临床医药杂志, 2022, 26(5): 44-47, 53. doi: 10.7619/jcmp.20214338
[2]	THEVENIN-LEMOINE B, BORNICHE D, UNTAS A, et al. Dialysis and quality of life: results of a national survey of patients on dialysis or with experience of dialysis[J]. Nephrol Ther, 2023, 19(2): 145-151. doi: 10.1684/ndt.2023.18
[3]	QIU C M, YANG X F, YU P. Sarcopenia: pathophysiology and treatment strategies[J]. Endocr Metab Immune Disord Drug Targets, 2023: EMIDDT-EPUB-131895.
[4]	吴佳盈, 丁苗佳, 沈水娟, 等. 尿毒症肌少症患病率及危险因素的Meta分析[J]. 中国中西医结合肾病杂志, 2023, 24(1): 33-38. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB202301012.htm
[5]	ELDER M, MOONEN A, CROWTHER S, et al. Chronic kidney disease-related sarcopenia as a prognostic indicator in elderly haemodialysis patients[J]. BMC Nephrol, 2023, 24(1): 138. doi: 10.1186/s12882-023-03175-5
[6]	LIN Y L, LIOU H H, WANG C H, et al. Impact of sarcopenia and its diagnostic criteria on hospitalization and mortality in chronic hemodialysis patients: a 3-year longitudinal study[J]. J Formos Med Assoc, 2020, 119(7): 1219-1229. doi: 10.1016/j.jfma.2019.10.020
[7]	BAE E, LEE T W, BAE W, et al. Impact of phase angle and sarcopenia estimated by bioimpedance analysis on clinical prognosis in patients undergoing hemodialysis: a retrospective study[J]. Medicine, 2022, 101(25): e29375. doi: 10.1097/MD.0000000000029375
[8]	程蕊, 王晶, 张克英, 等. 2019亚洲肌少症诊断共识下肌少症相关危险因素评估[J]. 河北医科大学学报, 2021, 42(12): 1421-1425. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX202112011.htm
[9]	姜敏敏, 李鲁. SF-36量表在血透患者中的性能测试[J]. 中国行为医学科学, 2003, 12(1): 31-33. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXX200301012.htm
[10]	ANDREW D. Survey of food offered to United Kingdom haemodialysis patients attending for dialysis Sessions in main dialysis centres and satellite units and international comparison[J]. Ren Replace Ther, 2023, 9(1): 10. doi: 10.1186/s41100-023-00466-3
[11]	ROSENBERG I H. Sarcopenia: origins and clinical relevance[J]. J Nutr, 1997, 127(5 Suppl): 990S-991S.
[12]	杜雯, 陈孜瑾, 陈晓农. 慢性肾脏病患者肌少症的诊治进展[J]. 中华肾脏病杂志, 2020, 36(2): 160-164.
[13]	FU C, YAN D, WANG L, et al. High prevalence of sarcopenia and myosteatosis in patients undergoing hemodialysis[J]. Front Endocrinol, 2023, 14: 1117438.
[14]	WATHANAVASIN W, BANJONGJIT A, AVIHINGSANON Y, et al. Prevalence of sarcopenia and its impact on cardiovascular events and mortality among dialysis patients: a systematic review and meta-analysis[J]. Nutrients, 2022, 14(19): 4077.
[15]	戴祺洁, 陶静, 华建武, 等. 维持性血液透析患者肌少症发生情况及其影响因素分析[J]. 实用临床医药杂志, 2020, 24(12): 103-106. doi: 10.7619/jcmp.202012029
[16]	JAUWERISSA R, MARBUN M B H, NUGROHO P, et al. Factors associated with sarcopenia in maintenance hemodialysis patients: a cross-sectional study[J]. Acta Med Indones, 2023, 55(1): 26-32.
[17]	LU H, LEI X, KLAASSEN C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats[J]. Kidney Int, 2006, 70(11): 1920-1928.
[18]	MIZHER A, HAMMOUDI H, HAMED F, et al. Prevalence of chronic pain in hemodialysis patients and its correlation with C-reactive protein: a cross-sectional study[J]. Sci Rep, 2023, 13: 5293.
[19]	臧华龙, 秦学祥, 翁敏. 口服营养补充剂对维持性血液透析病人肌少症及生存质量的影响[J]. 肠外与肠内营养, 2018, 25(6): 349-354. https://www.cnki.com.cn/Article/CJFDTOTAL-CWCN201806007.htm
[20]	杜雯, 陈孜瑾, 王雪洁, 等. 维持性血液透析患者肌少症的患病率及相关影响因素[J]. 中华肾脏病杂志, 2021, 37(5): 407-413. https://cdmd.cnki.com.cn/Article/CDMD-10570-1022757100.htm
[21]	SHU X Y, LIN T P, WANG H, et al. Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 145-158.
[22]	GHARIB M S, NAZEIH M S, EL SAID T E. Effect of intradialytic oral nutritional supplementation on nutritional markers in malnourished chronic hemodialysis patients: prospective randomized trial[J]. BMC Nephrol, 2023, 24(1): 125.
[23]	JU S H, LEE E J, SIM B C, et al. Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study[J]. Front Nutr, 2023, 10: 1069651.

Cited By

Get Citation

PDF

XML

Article views (145) PDF downloads (6)

Turn off MathJax

Article Contents

Abstract

References

Effects of individualized nutrition intervention on sarcopenia and quality of life in maintenance hemodialysis patients

Abstract

References

Catalog

Export File

Citation

Format

Content